peptides growth hormone release: Frequently asked questions

Switch from GHRP-6 or GHRP-2 to ipamorelin, which shows negligible ghrelin pathway activation in controlled trials. If combination therapy is required, pair ipamorelin with modified GRF 1-29 (a GHRH analogue without appetite effects) rather than compounds that activate orexigenic pathways. Caloric intake logs are insufficient to control for ghrelin-driven hunger. The endocrine signal overrides voluntary restriction in most subjects.

Switch to CJC-1295 with DAC, which has a 6–8 day half-life and sustains GH elevation with once-weekly subcutaneous administration. Pair it with a once-daily ghrelin agonist like MK-677, an orally active GHS-R1a agonist with a 4–6 hour half-life that produces GH pulses 90–120 minutes post-dose. This combination maintains elevated GH without requiring multiple daily injections.

This is expected. Hexarelin binds CD36 scavenger receptors in cardiac and other tissues, leading to receptor desensitization with chronic administration. Studies show blunted GH response by week 16 of daily hexarelin use, returning near baseline despite continued dosing. Switch to ipamorelin or rotate peptides using 4-week on / 2-week off cycles to prevent desensitization. Ipamorelin does not bind CD36 and maintains GH response over 24+ week protocols.

Use ipamorelin as a monotherapy or stacked with CJC-1295. Ipamorelin is the most selective GHS-R1a agonist available. It produces 13-fold GH increases without detectable cortisol, prolactin, or ACTH elevation at standard research doses. GHRP-2 and hexarelin both trigger cortisol spillover that confounds metabolic and stress-response studies.

Check hepatic IGF-1 conversion capacity. GH stimulates IGF-1 synthesis in the liver, but chronic stress, caloric restriction below maintenance, or vitamin D deficiency all impair this conversion. A 2021 study in Endocrine Reviews found that subjects in energy deficit (>500 kcal/day below TDEE) showed normal GH peaks but 40–60% lower IGF-1 responses compared to eucaloric controls. GH elevation without IGF-1 conversion indicates a downstream synthesis bottleneck, not peptide failure.

Reduce dosing frequency to every other day for 7–10 days to allow GHS-R1a receptor upregulation. This washout period restores 70–85% of initial response amplitude. Alternatively, switch compound classes (e.g., GHRP-2 to ipamorelin) to engage slightly different receptor conformations, which can bypass partial desensitisation. Continuous daily dosing without breaks causes progressive receptor downregulation that dose escalation cannot overcome.

Discard it immediately. Cloudiness or visible particles indicate protein aggregation or contamination. Properly reconstituted peptides should be clear and colorless. Aggregated peptide loses bioactivity and may trigger immune responses in research models. Store lyophilized peptides at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days.